Zogenix shares crater after FDA experts gun down new pain drug

By John Carroll After its pain drug was shot down in a lopsided vote among FDA experts on Friday and analysts weighed in with a dour assessment of its chances at the hands of regulators, ...

Biogen embraces Isis again in early-stage collaboration worth up to $630M

By John Carroll Less than a year after Biogen Idec ($BIIB) inked its first development pact with the antisense experts at Isis Pharmaceuticals ($ISIS), the big biotech has come back ...

Takeda’s oral successor to Velcade benefits blood cancer patients

By Ryan McBride Takeda has claimed victory with midstage study results for one of the most important experimental meds in its pipeline of cancer drugs, MLN9708, a potential successor ...

ASH: Pharmacyclics’ ibrutinib seizes center stage with promising leukemia results

By John Carroll Pharmacyclics ($PCYC) continued its drumbeat of positive data for its would-be chronic lymphocytic leukemia blockbuster ibrutinib, with large majorities of two groups ...

Amgen lunges for lead role in genetics research, bags deCODE for $415M

By John Carroll Two years after a pair of top biotech venture players brought struggling deCODE Genetics out of bankruptcy and reenergized its efforts to better understand the genetic ...

FDA panel painkiller decision leads toward new approach

Experts suggest tamper-resistant issues get settled first By Eric Palmer There is abuse of power and then there is power over abuse and that is what an FDA panel exercised Friday ...

Merck wins back $500K in retaliation lawsuit

By Eric Palmer The courts giveth and the courts taketh away, and how you view those actions depends on which side of a lawsuit you sit on. In a recent ruling by a federal appeals court, ...

Pay-for-delay to get Supreme consideration

With Justice Alito dropping out, a 4-4 tie is possible By Eric Palmer The U.S. Supreme Court will decide once and for all whether paying generic competitors to hold off on entering ...

Bloomberg: SEC looking at InterMune trades by hedge fund

By Eric Palmer The Securities and Exchange Commission is looking harder at SAC Capital Advisors to see if there is a connection to insider trading on InterMune ($ITMN) stock, Bloomberg reports. Citing ...

Eliquis from Pfizer, Bristol-Myers Squibb shows potential for longer use

FDA will consider the blood thinner in March for the third time By Eric Palmer Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) have racked up more good news for their blood thinner Eliquis, ...

GE Healthcare vet to lead Israeli devicemaker

GE also invests in InSightec, which makes a focused ultrasound surgical tool By Mark Hollmer GE Healthcare ($GE), a longtime investor in Israel’s InSightec, recently strengthened ...

Swedish Dx player enters U.S. market

By Mark Hollmer Euro Diagnostica, a Swedish player in the ever-growing diagnostics market, is making its way to North America, thanks to a new deal with a major distributor. The American ...
Page 1 of 7012345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS